BMS at AAD VMX 2021

Intended for U.S. scientific audiences only.

The American Academy of Dermatology’s (AAD) Virtual Meeting Experience (VMX) 2021 is an important opportunity for scientific exchange on research and breakthroughs for patients living with dermatologic diseases. We look forward to showcasing new research and sharing progress for patients with immune-mediated diseases.

Samit Hirawat on BMS’ presence at AAD VMX 2021

Hear from Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, about Bristol Myers Squibb’s presence at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) and the company’s commitment to patients living with psoriasis and other immune-mediated diseases.

Our Data at AAD VMX 2021

Read more about our key data being presented at the meeting.

At AAD VMX 2021, Bristol Myers Squibb is presenting Phase 3 data of an investigational compound in moderate to severe plaque psoriasis.

Our Science   

We are committed to improving the lives of patients with immune-mediated diseases, like psoriasis, and remain steadfast in exploring additional potential treatment options that might provide benefit for patients where unmet need still exists. Learn more here.

Driving Forward Dermatology Research: A Q&A with Mary Beth Harler  >

Learn about Bristol Myers Squibb’s approach and commitment to dermatology research from Mary Beth Harler, senior vice president and head of Immunology and Fibrosis Development.

Pioneering New Paths Forward in Psoriasis  >

Renata Kisa, worldwide medical lead, Dermatology, provides insight into the current unmet needs for patients with psoriasis, and explores the need for differentiated treatment options.

Destination: The Impact of Precision Medicine in Disease Management for People with Immune-Mediated Diseases  >

Brian Gavin, development lead, discusses Bristol Myers Squibb’s approach to unlocking the full potential of precision medicine for immune-mediated diseases.

Pursuing Innovative Approaches to Advance Research for Psoriatic Disease  >

Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.


Our research in Immunology and dermatology follows a science-driven pathway approach that delivers scientific innovation across key areas of focus.

TYK2 Pathway Fact Sheet  >

Learn about the scientific mechanism behind the TYK2 pathway and its role in immune-mediated diseases.

Learn about the TYK2 pathway and its role in immune-mediated diseases like psoriasis.

Psoriasis  >

Learn more about psoriasis, its symptoms and potential impact on patients.